$TEM

West Nadja sold $162K of TEM

West Nadja sold 3,000 shares of Tempus AI, Inc. (TEM) at $53.90 ($0.16M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · West Nadja
Published Aug 18, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 8:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TEM
Neutral
high confidence
Mentioned
$TEM
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details: 3,000 shares at $53.90 on 2026-08-14, with holdings after the sale of 34,981 shares, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may log the insider sale for sentiment monitoring, but the 10b5-1 structure makes it less actionable as a standalone catalyst.

03

What to watch

The article does not provide context on total holdings, prior sale frequency, or whether the sale was tax-related, limiting inference from the transaction size.

Relevance 3/10Novelty 3/10Timing: Filed 2026-08-18, disclosing an insider sale executed 2026-08-14.

Background

The article is an SEC Form 4 insider transaction disclosure for Tempus AI, Inc. (TEM).

Company-level read

Ticker impact

$TEMNeutralHigh confidence
Context

Tempus AI director West Nadja sold 3,000 shares in an open-market transaction at $53.90 on 2026-08-14 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider transaction, but it specifies a 10b5-1 pre-arranged plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution, so traders may watch for follow-on sales or other insider activity.

Key entities

  • Tempus AI, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • West Nadja

    Director who sold 3,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TEMMedAI 9/10

Tempus AI (TEM) Jumped on Moderna’s Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated?

Tempus AI (TEM) shares rose after Moderna and Merck reported positive Phase 3 trial results for a personalized cancer therapy, validating Personalis' sequencing technology. Tempus agreed to acquire Personalis for $1.5B, with the deal pending. Personalis' technology is distinct from the main target of the acquisition, NeXT Personal, a tumor-informed molecular residual disease test. Tempus reported 9,000 MRD tests in Q2, while Personalis generated $22.357M in revenue and delivered 10,384 clinical

$TEMMedAI 8/10

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

Tempus AI, Inc. (NASDAQ: TEM) received FDA clearance for its AI product, Tempus ECG-PH, designed to detect signs of pulmonary hypertension from standard ECGs. This is the third FDA-cleared cardiovascular device in Tempus' portfolio, aiming to help clinicians identify at-risk patients earlier. The product analyzes ECG data but is not intended for standalone diagnosis.

$TEMHighAI 8/10

Why Tempus AI Skyrocketed This Week

Tempus AI (TEM) shares rose 39.5% this week after Merck and Moderna reported positive Phase 3 trial data for their cancer vaccine, which uses technology from Personalis, a company Tempus is acquiring. Tempus's market cap is $13B, and its stock is still down about 10% over the past year. The acquisition is expected to close late 2024 or early 2027.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.